Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws

被引:46
作者
Klingelhoeffer, Christoph [1 ]
Zeman, Florian [2 ]
Meier, Johannes [1 ]
Reichert, Torsten Eugen [1 ]
Ettl, Tobias [1 ]
机构
[1] Hosp Univ Regensburg, Dept Cranio & Maxillofacial Surg, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany
[2] Hosp Univ Regensburg, Dept Clin Studies, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany
关键词
Bisphosphonates; Denosumab; Osteonecrosis; Surgery; Recurrence; BISPHOSPHONATE-RELATED OSTEONECROSIS; ZOLEDRONIC ACID; CANCER-PATIENTS; BONE METASTASES; BREAST-CANCER; MANAGEMENT; DENOSUMAB; PREVALENCE; RESECTION; SHOWS;
D O I
10.1016/j.jcms.2016.08.001
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Purpose: Surgical treatment of the medication-related osteonecrosis of the jaw (MRONJ) is still challenging. We examined the outcome of the resection of osteonecrotic lesions and the influence of potential risk factors on the operative success. Methods: Seventy six surgical interventions on 40 patients were evaluated in a prospective design with a mean follow-up of 55 weeks. Primary endpoints were: (i) maintenance of the mucosal closure and (ii) decrease of MRONJ stage. Influential variables included preoperative duration, location and diameter of MRONJ, duration and change of antiresorptive therapy, presence of actinomyces species. Results: Only in 27.6% of cases long-term maintenance of the mucosal closure was achieved. However, stage II patients decreased to stage I in 81% after surgery (p < 0.01) and stage III patients improved in 83% of cases (OR = 8.08; p = 0.07). Stage I patients profited only in 38% by surgical intervention. MRONJ recurrence after surgery was associated with extended preoperative MRONJ duration (p = 0.015). There was no significance of further influential variables, but MRONJ of the upper jaw seems prognostically more favorable. Conclusion: Advanced stages of MRONJ benefit from surgical treatment, whereas stage I diseases may also be treated conservatively. An early intervention reduces the risk of recurrence. (C) 2016 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:1694 / 1699
页数:6
相关论文
共 35 条
[1]   Value of nonsurgical therapeutic management of stage I bisphosphonate-related osteonecrosis of the jaw [J].
Bodem, Jens Philipp ;
Kargus, Steffen ;
Engel, Michael ;
Hoffmann, Juergen ;
Freudlsperger, Christian .
JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2015, 43 (07) :1139-1143
[2]   The Role of Surgical Resection in the Management of Bisphosphonate-Related Osteonecrosis of the Jaws [J].
Carlson, Eric R. ;
Basile, John D. .
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2009, 67 (05) :85-95
[3]   AMERICAN ASSOCIATION OF ORAL AND MAXILLOFACIAL SURGEONS POSITION PAPER: BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAWS-2009 UPDATE: THE NEED TO REFINE THE BRONJ DEFINITION [J].
Colella, Giuseppe ;
Campisi, Giuseppina ;
Fusco, Vittorio .
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2009, 67 (12) :2698-2699
[4]   Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer [J].
Coleman, R. ;
Woodward, E. ;
Brown, J. ;
Cameron, D. ;
Bell, R. ;
Dodwell, D. ;
Keane, M. ;
Gil, M. ;
Davies, C. ;
Burkinshaw, R. ;
Houston, S. J. ;
Grieve, R. J. ;
Barrett-Lee, P. J. ;
Thorpe, H. .
BREAST CANCER RESEARCH AND TREATMENT, 2011, 127 (02) :429-438
[5]   Treatment of bisphosphonate-related osteonecrosis of the jaws: presentation of a protocol and an observational longitudinal study of an Italian series of cases [J].
Ferlito, Sebastiano ;
Puzzo, Sergio ;
Palermo, Filippo ;
Verzi, Placido .
BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2012, 50 (05) :425-429
[6]   Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study [J].
Fizazi, Karim ;
Carducci, Michael ;
Smith, Matthew ;
Damiao, Ronaldo ;
Brown, Janet ;
Karsh, Lawrence ;
Milecki, Piotr ;
Shore, Neal ;
Rader, Michael ;
Wang, Huei ;
Jiang, Qi ;
Tadros, Sylvia ;
Dansey, Roger ;
Goessl, Carsten .
LANCET, 2011, 377 (9768) :813-822
[7]   Resective Surgical Approach Shows a High Performance in the Management of Advanced Cases of Bisphosphonate-Related Osteonecrosis of the Jaws: A Retrospective Survey of 347 Cases [J].
Graziani, Filippo ;
Vescovi, Paolo ;
Campisi, Giuseppina ;
Favia, Gianfranco ;
Gabriele, Mario ;
Gaeta, Giovanni Maria ;
Gennai, Stefano ;
Goia, Franco ;
Miccoli, Mario ;
Peluso, Franco ;
Scoletta, Matteo ;
Solazzo, Luigi ;
Colella, Giuseppe .
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2012, 70 (11) :2501-2507
[8]   The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid Data from the Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly clinical trials program [J].
Grbic, John T. ;
Black, Dennis M. ;
Lyles, Kenneth W. ;
Reid, David M. ;
Orwoll, Eric ;
McClung, Michael ;
Bucci-Rechtweg, Christina ;
Su, Guoqin .
JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 2010, 141 (11) :1365-1370
[9]  
Gupta Swati, 2013, Natl J Maxillofac Surg, V4, P151, DOI 10.4103/0975-5950.127643
[10]   Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis [J].
Hansen, T ;
Kunkel, M ;
Weber, A ;
Kirkpatrick, CJ .
JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2006, 35 (03) :155-160